TD Asset Management’s Orchestra BioMed OBIO Stock Holding History

TD Asset Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-45,692	Closed	-$190K	–	1274
2025 Q4	$190K	Sell	45,692 -46,986	-51%	-$190K	﹤0.01%	1224
2025 Q3	$230K	Hold	92,678	–	–	﹤0.01%	1214
2025 Q2	$248K	Hold	92,678	–	–	﹤0.01%	1171
2025 Q1	$397K	Hold	92,678	–	–	﹤0.01%	1167
2024 Q4	$371K	Hold	92,678	–	–	﹤0.01%	1197
2024 Q3	$465K	Hold	92,678	–	–	﹤0.01%	1309
2024 Q2	$755K	Hold	92,678	–	–	﹤0.01%	1209
2024 Q1	$488K	Hold	92,678	–	–	﹤0.01%	1299
2023 Q4	$846K	Hold	92,678	–	–	﹤0.01%	1211
2023 Q3	$808K	Buy	92,678 +46,339	+100%	+$312K	﹤0.01%	1181
2023 Q2	$324K	Hold	46,339	–	–	﹤0.01%	1330
2023 Q1	$907K	Hold	46,339	–	–	﹤0.01%	1150
2022 Q4	$463K	Hold	46,339	–	–	﹤0.01%	1298
2022 Q3	$459K	Hold	46,339	–	–	﹤0.01%	1311
2022 Q2	$462K	Hold	46,339	–	–	﹤0.01%	1301
2022 Q1	$459K	Hold	46,339	–	–	﹤0.01%	1350
2021 Q4	$463K	Hold	46,339	–	–	﹤0.01%	1394
2021 Q3	$458K	Hold	46,339	–	–	﹤0.01%	1403
2021 Q2	$459K	Hold	46,339	–	–	﹤0.01%	1395
2021 Q1	$520K	Hold	46,339	–	–	﹤0.01%	1390
2020 Q4	$594K	Buy	+46,339	New	+$528K	﹤0.01%	1301

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

TD Asset Management's OBIO Position: Q1 2026 in Review

TD Asset Management sold out of Orchestra BioMed (OBIO) in Q1 2026, closing a stake of 45,692 shares — an estimated $190K sold.

TD Asset Management first reported a position in OBIO in Q4 2020 and held it in 21 quarters. The position peaked at $907K in Q1 2023. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

TD Asset Management reported no remaining Orchestra BioMed position as of Q1 2026 after selling out during the quarter.
TD Asset Management sold 45,692 Orchestra BioMed shares in Q1 2026, an estimated $190K.
TD Asset Management first reported a position in Orchestra BioMed in Q4 2020 and held it in 21 quarters.
TD Asset Management's Orchestra BioMed position peaked at $907K in Q1 2023.
65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.